Active Clinical Trials at OOS

All Clinical Trials

ASTX030-01

Tumor site:
Hematologic (MDS, CMML, AML)
Description:
A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Available at:
Our Salem Office
More info:
See this trial on ClinicalTrials.gov »
Notes:
Sponsor: Astex; NCT Number: NCT04256317

Amplitude (67652000PCR3002)

Tumor site:
Prostate
Description:
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Available at:
Our Salem Office
More info:
See this trial on ClinicalTrials.gov »
Notes:
Sponsor: Janssen; NCT Number: NCT04497844

BDX-00146

Tumor site:
Lung
Description:
***Enrollment closing soon*** An Observational Study Assessing the Clinical Effectiveness of the VeriStrat® Test and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer (INSIGHT)
Available at:
Our Salem Office
More info:
See this trial on ClinicalTrials.gov »
Notes:
Sponsor: Biodesix Inc; NCT Number: NCT03289780

Bespoke 20-041-NCP

Tumor site:
Colorectal
Description:
***Enrollment closed*** An Observational Study of ctDNA Guided Therapy in Colorectal Cancer.
Available at:
Our Salem Office
More info:
See this trial on ClinicalTrials.gov »
Notes:
Sponsor: Natera Inc; NCT Number: NCT04264702

EQ132-201

Tumor site:
Breast
Description:
A Phase 2 Study to Evaluate the Safety and Efficacy of Lerociclib in Participants with Advanced Breast Cancer
Available at:
Our Salem Office
More info:
See this trial on ClinicalTrials.gov »
Notes:
Sponsor: EQRx, Inc; NCT Number: NCT05085002

LOXO-BTK-20019

Tumor site:
Mantle Cell Lymphoma
Description:
***Enrollment closed*** A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Available at:
Our Salem Office
More info:
See this trial on ClinicalTrials.gov »
Notes:
Sponsor: Loxo Oncology, Inc; NCT Number: NCT04662255

INTRINSIC

Tumor site:
Colorectal Cancer
Description:
A Phase I/Ib global, multicenter, open-label umbrella study evaluating the safety and efficacy of targeted therapies in subpopulations of patients with metastatic colorectal cancer
Available at:
Our Salem Office
More info:
See this trial on ClinicalTrials.gov »
Notes:
Sponsor: Roche; NCT Number: NCT04929223

Mirati KRYSTAL 7

Tumor site:
Lung (NSCLC)
Description:
Phase 2 Trial of MRTX849 Plus Pembrolizumab for NSCLC With KRAS G12C Mutation (KRYSTAL-7)
Available at:
Our Salem Office
More info:
See this trial on ClinicalTrials.gov »
Notes:
Sponsor: Mirati Therapeutics Inc; NCT Numer: NCT04613596

PARADIGM

Tumor site:
NSCLC, Melanoma, Renal Cell Carcinoma, Triple Negative Breast Cancer
Description:
***Enrollment closed*** PARADIGM: Pursuit to Analyze and Reveal Associated Drivers of Immunotherapy outcomes through the Gut Microbiome
Available at:
Our Salem Office
More info:
See this trial on ClinicalTrials.gov »
Notes:
Sponsor: VastBiome; NCT Number: NCT05037825

VIKTORIA-1

Tumor site:
Breast
Description:
A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
Available at:
Our Salem Office
More info:
See this trial on ClinicalTrials.gov »
Notes:
Sponsor: Celcuity; NCT Number: NCT05501886
Page 1 of
Page: